切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (03) : 237 -240. doi: 10.3877/cma.j.issn.1674-3946.2020.03.008

所属专题: 文献

论著

联合肝叶及血管切除重建根治术治疗肝动脉受侵肝门部胆管癌的近期随访
朱学河1, 马丽杰2, 吴魏1,()   
  1. 1. 010050 内蒙古医科大学附属医院
    2. 010050 内蒙古医科大学
  • 收稿日期:2019-12-31 出版日期:2020-06-26
  • 通信作者: 吴魏

Short-term follow-up of combined lobectomy with arterial resection and reconstruction for hilar cholangiocarcinoma

Xuehe Zhu1, Lijie Ma2, Wei Wu1,()   

  1. 1. Affiliated Hospital of Inner Mongolia Medical University 010050
    2. Inner Mongolia Medical University 010050
  • Received:2019-12-31 Published:2020-06-26
  • Corresponding author: Wei Wu
  • About author:
    Corresponding author: Wu Wei, Email:
  • Supported by:
    National Natural Science Foundation of China(2016MS08134)
引用本文:

朱学河, 马丽杰, 吴魏. 联合肝叶及血管切除重建根治术治疗肝动脉受侵肝门部胆管癌的近期随访[J]. 中华普外科手术学杂志(电子版), 2020, 14(03): 237-240.

Xuehe Zhu, Lijie Ma, Wei Wu. Short-term follow-up of combined lobectomy with arterial resection and reconstruction for hilar cholangiocarcinoma[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(03): 237-240.

目的

探讨联合肝叶及血管切除重建根治术治疗肝动脉受侵肝门部胆管癌(HCCA)的临床效果和预后情况。

方法

回顾性分析2016年10月至2019年10月肝动脉受侵HCCA患者98例资料,根据手术方式不同将患者分为联合组(HCCA根治术+肝叶切除+肝动脉切除重建术)51例和姑息组(姑息性胆管肿瘤切除术/内引流减黄手术)47例。所有数据均采用SPSS22.0软件处理分析,两组患者术中术后各项指标以(±s)表示,采用独立样本t检验。并发症比较采用χ2检验;采用Kaplanmeier绘制患者的生存曲线;以P<0.05为差异有统计学意义。

结果

联合组手术时间、住院费用明显高于姑息组,但术中出血量、住院时间明显低于姑息组(P<0.05)。联合组并发症发生率为52.9%,与姑息组的42.6%比较,差异无统计学意义(P>0.05);两组均未发生围术期死亡。随访时间截至2019年11月,联合组的1年、2年、3年生存率分别为84.3%、66.7%、43.1%,,明显高于姑息组的17.0%、10.6%、4.3%(P<0.05)。

结论

联合肝叶及血管切除重建根治术用于治疗肝动脉受侵HCCA,可有效减少术中出血量,提高患者的生存率。

Objective

To investigate the clinical effect and prognosis of combined lobectomy with arterial resection and reconstruction for patients of hepatic artery invasion of hilar cholangiocarcinoma(HCCA).

Methods

98 cases of HCCA with hepatic artery invasion from October 2016 to October 2019 were retrospectively analyzed. According to different surgical methods, the patients were divided into combined group (HCCA radical surgery + lobectomy + hepatic artery resection, 51 cases) and palliative group (palliative bile duct tumor resection / internal drainage reduction surgery, 47 cases). All the data were analyzed by spss22.0 software. The indexes of the patients in the two groups were expressed by (±s), and independent sample t test was used to compare. The complications were compared by χ2 test, Kaplan-Meier was used to plot the survival curve of patients, and P<0.05 was considered statistically significant.

Results

The operation time and hospitalization cost in the combined group were significantly higher than those in the palliative group. The intraoperative blood loss and hospital stay in the combined group were significantly lower than those in the palliative group, and the differences were statistically significant (P<0.05). The complication rate in the combined group was 52.9%, compared with 42.5% in the palliative group, the difference was not statistically significant (P>0.05); no perioperative death occurred in both groups. The follow-up time was up to November 2019. After 1 to 36 months of follow-up, all patients in the combined group had a one-year survival rate, a two-year survival rate, and a three-year survival rate of 84.3%, 66.7%, and 43.1%, which were significantly higher than 17.0%, 10.6%, 4.3% in the palliative group, the differences were statistically significant (P<0.05).

Conclusion

The combined lobectomy with arterial resection and reconstruction can effectively reduce the amount of bleeding and improve the survival rate of patients with HCCA.

表1 98例肝动脉受侵HCCA患者不同术式两组一般资料比较[(±s),例]
表2 98例肝动脉受侵HCCA患者不同术式两组术中术后各项指标比较(±s)
表3 98例肝动脉受侵HCCA患者不同术式两组并发症发生率比较(例)
图1 98例肝动脉受侵HCCA患者不同术式两组患者术后生存曲线
表4 98例肝动脉受侵HCCA患者不同术式两组生存率比较 [例(%)]
[1]
胡海洁,靳艳文,林圯昕,等.肝门部胆管癌肿瘤直径及相关预后指标对患者预后的影响因素分析[J].中华消化外科杂志,2018,17(3):266-272.
[2]
戴伟,钱叶本.Bismuth-CorletteⅢ型肝门部胆管癌治疗策略[J].中华普通外科杂志,2019,34(1):14-17.
[3]
李敏,宋洁琼,宋陆军,等.术前吲哚菁绿清除试验预测肝门部胆管癌患者肝储备功能[J].中华肝胆外科杂志,2019,25(8):565-569.
[4]
倪传斗,宋春峰,杨明军,等.肝门部胆管癌的术前评估和外科治疗现状[J].国际肿瘤学杂志,2018,45(11):692-695.
[5]
陈明.66例肝门胆管癌合并阻塞性黄疸病例介入治疗的回顾性分析[J/CD].中华普外科手术学杂志(电子版),2019,13(5):501-503.
[6]
徐霖,俞文隆,于观贞,等.ALDH1A1和ALDH6A1在肝门部胆管癌中的表达及其临床意义[J].临床肿瘤学杂志,2017,22(11):990-995.
[7]
张登勇,孙万亮,马翔,等.肝门胆管癌70例临床诊治分析[J].中华医学杂志,2019,99(4):284-287.
[8]
Loveday BPT, Knox JJ, Dawson LA,et al.Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada[J].J Surg Oncol,2018,117(2):213-219.
[9]
徐后云,余细平,冯锐,等.肝癌患者肝动脉化疗栓塞术后相关性胆管损伤与血管栓塞位置的关系及临床预后分析[J].中华肿瘤杂志,2017,39(5):355-360.
[10]
戴海粟,别平,王曙光,等.联合肝动脉切除重建在肝门部胆管癌根治术中的临床研究[J].中华外科杂志,2018,56(1):41-46.
[11]
Malik A, Robinson S, French J,et al.Chemotherapy for hilar cholangiocarcinoma (HCCA): Outcomes in a tertiary referral centre[J].European Journal of Surgical Oncology,2018,44(11):S16.
[12]
Malik AK, Robinson SM, French JJ,et al.Surgery for Hilar cholangiocarcinoma: the Newcastle upon Tyne Liver Unit experience[J].European Surgery,2019,51(4):197-205.
[13]
金望迅,王兵,黄灵,等.影响二步肝切除术肝脏再生的主要因素研究[J].中华全科医学,2019,17(6):927-931,1032.
[14]
朱飞鹏,季顾惟,刘希胜,等.多排螺旋CT评估肝门部胆管癌胆道侵犯的准确性[J].中国临床研究,2017,30(12):1593-1596.
[15]
陈琳,陈孝平.肝门部胆管癌个体化治疗的现状与思考[J].国际外科学杂志,2018,45(6):361-363.
[16]
杨建明,杨丹丹,张伟浩,等.肝门部胆管癌术后常见并发症的预防与处理[J].腹部外科,2019,32(1):68-71.
[17]
刘百铭,苏洋.肝门部胆管癌手术治疗争议点的研究现状[J].中国医师进修杂志,2019,42(5):467-470.
[18]
田立斌,张海光,鲁鑫,等.淋巴增强因子1及细胞周期蛋白D1在肝门部胆管癌中的表达及其临床意义[J].临床与病理杂志,2018,38(5):942-946.
[19]
Aloia TA.Precision Hilar Cholangiocarcinoma Surgery[J].Ann Surg Oncol,2018,25(5):1103-1104.
[20]
Poruk KE, Pawlik TM, Weiss MJ.Perioperative Management of Hilar Cholangiocarcinoma[J].J Gastrointest Surg,2015,19(10):1889-1899.
[21]
Mansour JC, Aloia TA, Crane CH,et al.Hilar cholangiocarcinoma: expert consensus statement[J].HPB(Oxford),2015,17(8):691-699.
[1] 李佳隆, 韩青雷, 宋铭杰, 古丽米拉·亚森江, 钟锴, 蒋铁民, 郭强, 吐尔干艾力·阿吉, 邵英梅. Bismuth-Corlette Ⅱ型肝门部胆管癌行扩大肝切除与围肝门切除的临床疗效分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 438-443.
[2] 王春荣, 陈姜, 喻晨. 循Glisson蒂鞘外解剖、Laennec膜入路腹腔镜解剖性左半肝切除术临床应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 37-40.
[3] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[4] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[5] 汤海琴, 郭秀枝, 朱晓素, 赵世娣. “隧道法”腹腔镜解剖性左半肝切除术的临床安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 674-677.
[6] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[7] 王兴, 张峰伟. 腹腔镜肝切除联合断面射频消融治疗伴微血管侵犯肝细胞癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 580-583.
[8] 陈忠垚, 陈胜灯, 李秋. 不同手术时机对原发性肝癌自发破裂出血患者远期预后的影响[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 518-521.
[9] 李婷婷, 吴荷玉, 张悦, 程康, 张晓芳, 程娅婵. 复合保温策略在老年腹腔镜解剖性肝切除术中的应用研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 522-525.
[10] 刘波, 涂志坚, 李传富, 李江涛, 陈国栋. 机器人解剖性左半肝切除术[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 486-486.
[11] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[12] 廖梅, 张红君, 金洁玚, 吕艳, 任杰. 床旁超声造影对肝移植术后早期肝动脉血栓的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 630-634.
[13] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[14] 唐灿, 李向阳, 秦浩然, 李婧, 王天云, 柯阳, 朱红. 原发性肝脏神经内分泌肿瘤单中心12例诊治与疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 674-680.
[15] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
阅读次数
全文


摘要